Drug Price Transparency Insurance Premium Reductions
| Type | Bill |
|---|---|
| Session | 2020 Regular Session |
| Subjects |
Concerning measures to reduce health care costs related to prescription drug prices, and, in connection therewith, creating the "Colorado Prescription Drug Price Transparency Act of 2020" to require health insurers, prescription drug manufacturers, pharmacy benefit management firms, and nonprofit organizations to report specified information about the costs of prescription drugs to the commissioner of insurance and to direct the commissioner to analyze the information and submit a report regarding the effects of prescription drug costs on health insurance premiums; and requiring health insurers to reduce insurance premiums to adjust for rebates the insurers receive for prescription drugs.
Bill Summary:
Section 1 of the bill enacts the "Colorado Prescription Drug Price TransparencyAct of 2020", which requires:
- Health insurers, starting in 2021, to submit to the commissioner of insurance (commissioner) information regarding prescription drugs covered under their health insurance plans that the health insurers paid for in the preceding calendar year, including information about rebates received from prescription drug manufacturers, a certification regarding how rebates were accounted for in insurance premiums, and a list of all pharmacy benefit management firms (PBMs) with whom they contract;
- Prescription drug manufacturers to notify the commissioner, state purchasers, health insurers, PBMs, pharmacies, and hospitals when the manufacturer, on or after January 1, 2021, increases the price of certain prescription drugs by more than specified amounts or introduces a new specialty drug in the commercial market;
- Prescription drug manufacturers, within 15 days after the end of each calendar quarter that starts on or after January 1, 2021, to provide specified information to the commissioner regarding the drugs about which the manufacturer notified purchasers;
- Health insurers or, if applicable, PBMs to annually report specified information to the commissioner regarding rebates and administrative fees received from manufacturers for prescription drugs they paid for in the prior calendar year and the average wholesale price paid for prescription drugs by individuals, small employers, and large employers enrolled in health plans issued by the health insurer or that contain prescription drug benefits managed or administered by the PBM; and
- Certain nonprofit organizations to compile and submit to the commissioner an annual report indicating the amount of each payment, donation, subsidy, or thing of value received by the nonprofit organization or its officers, employees, or board members from a prescription drug manufacturer, PBM, health insurer, or trade association and the percentage of the nonprofit organization's total gross income that is attributable to those payments, donations, subsidies, or things of value.
Health insurers that fail to report the required data are subject to a fine of up to $10,000 per day per report. Nonprofit organizations are subject to a fine of up to $10,000 for failure to comply with reporting requirements.
Section 2 specifies that failing to ensure that a PBM that a health insurer uses to manage or administer its prescription drug benefits is complying with reporting requirements constitutes an unfair method of competition and an unfair or deceptive act or practice in the business of insurance.
Section 3 specifies that a PBM is an entity that manages or administers prescription drug benefits for a health insurer, either pursuant to a contract or as an entity associated with the health insurer.
Under sections 4 and 5 , a prescription drug manufacturer that fails to notify purchasers or fails to report required data to the commissioner is subject to discipline by the state board of pharmacy, including a penalty of up to $10,000 per day for each day the manufacturer fails to comply with the notice or reporting requirements. The commissioner is to report manufacturer violations to the state board of pharmacy.
Section 6 requires a health insurer to reduce premiums for the health plans it issues or renews on or after January 1, 2022, to adjust for the rebates the health insurer received from prescription drug manufacturers in the previous plan year.
(Note: This summary applies to this bill as introduced.)
Prime Sponsors
Representative
Dominique Jackson
Representative
Dylan Roberts
Senator
Joann Ginal
Senator
Kerry Donovan
Committees
Related Documents & Information
| Date | Version | Documents |
|---|---|---|
| 01/21/2020 | Introduced |
| Date | Version | Documents |
|---|---|---|
| 03/12/2020 | SA1 |
| Activity | Vote | Documents |
|---|---|---|
| Adopt amendment J.001 | The motion passed without objection. | Vote summary |
| Refer House Bill 20-1160, as amended, to the Committee of the Whole. | The motion passed on a vote of 7-4. | Vote summary |
| Activity | Vote | Documents |
|---|---|---|
| Refer House Bill 20-1160 to the Committee on Appropriations. | The motion passed on a vote of 7-4. | Vote summary |
| Activity | Vote | Documents |
|---|---|---|
| Adopt amendment L.006 (Attachment D) to L.002 (Attachment B). | The motion passed without objection. | Vote summary |
| Adopt amendment L.002, as amended (Attachment B). | The motion passed without objection. | Vote summary |
| Adopt amendment L.004 (Attachment C). | The motion passed without objection. | Vote summary |
| Adopt amendment L.003 (Attachment G). | The motion failed on a vote of 4-6. | Vote summary |
| Refer House Bill 20-1160, as amended, to the Committee on Finance. | The motion passed on a vote of 7-3. | Vote summary |
| Date | Amendment Number | Committee/ Floor Hearing | Status | Documents |
|---|---|---|---|---|
| 03/13/2020 | J.001 | HOU Appropriations | Passed [*] | |
| 02/12/2020 | L.003 | HOU Health & Insurance | Lost | |
| 02/12/2020 | L.004 | HOU Health & Insurance | Passed [*] | |
| 02/12/2020 | L.002 | HOU Health & Insurance | Passed [*] | |
| 02/12/2020 | L.006 | HOU Health & Insurance | Passed [*] |
| Date | Location | Action |
|---|---|---|
| 06/01/2020 | House | House Second Reading Laid Over Daily - No Amendments |
| 05/28/2020 | House | House Second Reading Laid Over to 06/01/2020 - No Amendments |
| 03/13/2020 | House | House Committee on Appropriations Refer Amended to House Committee of the Whole |
| 03/02/2020 | House | House Committee on Finance Refer Unamended to Appropriations |
| 02/12/2020 | House | House Committee on Health & Insurance Refer Amended to Finance |
| 01/21/2020 | House | Introduced In House - Assigned to Health & Insurance + Appropriations |
Prime Sponsor
Sponsor
Co-Sponsor